C07K 16/2848
Against integrin beta3-subunit-containing molecules
Official title: {against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61}
C07K16/2848 (Against integrin beta3-subunit-containing molecules) appears on 182 US grants and 280 published applications in this corpus.
Search patents in C07K- Granted patents
- 182
- Published applications
- 280
- Assignees
- 136
- Inventors
- 410
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 5 | 0 |
| 1994 | 1 | 0 |
| 1995 | 4 | 0 |
| 1996 | 3 | 0 |
| 1997 | 4 | 0 |
| 1998 | 6 | 0 |
| 1999 | 3 | 0 |
| 2000 | 2 | 0 |
| 2001 | 5 | 3 |
| 2002 | 4 | 9 |
| 2003 | 7 | 14 |
| 2004 | 2 | 20 |
| 2005 | 4 | 11 |
| 2006 | 3 | 10 |
| 2007 | 5 | 11 |
| 2008 | 5 | 6 |
| 2009 | 7 | 16 |
| 2010 | 7 | 16 |
| 2011 | 3 | 11 |
| 2012 | 6 | 13 |
| 2013 | 16 | 10 |
| 2014 | 6 | 12 |
| 2015 | 6 | 6 |
| 2016 | 5 | 11 |
| 2017 | 7 | 14 |
| 2018 | 10 | 14 |
| 2019 | 5 | 7 |
| 2020 | 4 | 13 |
| 2021 | 13 | 13 |
| 2022 | 3 | 12 |
| 2023 | 7 | 10 |
| 2024 | 4 | 9 |
| 2025 | 5 | 3 |
| 2026 | 4 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treating cancer6 Oct 2026US 12,753,236 B2Alpha Beta Holdings, LLC
- αv-integrin targeted small molecule drug conjugates12 May 2026US 12,624,109 B2TargetThera LLC
- Methods for treating drug resistant cancers14 Apr 2026US 12,601,743 B2The Regents of the University of California
- Antigen-binding molecule containing modified Fc region13 Jan 2026US 12,522,648 B2Chugai Seiyaku Kabushiki Kaisha
- Antigen-binding molecule containing modified antibody variable region25 Nov 2025US 12,479,916 B2Chugai Seiyaku Kabushiki Kaisha
- Combination therapies with an anti-factor xi/factor xia antibody13 Aug 2026US 2026/0232796 A1Anthos Therapeutics, Inc.
- Antigen-binding molecule containing modified fc region18 Jun 2026US 2026/0167699 A1Chugai Seiyaku Kabushiki Kaisha
- Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers11 Jun 2026US 2026/0159592 A1The Regents of the University of California
- Glycotargeting therapeutics30 Apr 2026US 2026/0115300 A1Ecole Polytechnique Federale De Lausanne (Epfl)
- Methods of screening and expressing cis-display libraries of disulfide-rich polypeptides2 Apr 2026US 2026/0092274 A1Applied Biomedical Science Institute
Most cited
By later US patents
- Humanization of murine antibody319US 7,087,409 B2The Scripps Research Institute · 2006
- Platelet-specific chimeric 7E3 immunoglobulin139US 5,770,198 ACentocor, Inc. · 1998
- Humanized antibodies reactive with GPIIB/IIIA107US 5,777,085 AProtein Design Labs, Inc. · 1998
- Anti-integrin antibodies, compositions, methods and uses101US 7,163,681 B2Centocor, Inc. · 2007
- Mutant antibody Fc domains and fusion proteins thereof95US 8,409,568 B2MedImmune, LLC · 2013